Cognito Therapeutics closed a $105 million Series C to propel its Spectris non‑invasive brain‑stimulation platform through pivotal development for Alzheimer’s disease and to scale operations for an at‑home prescription therapy. The oversubscribed round was led by institutional investors and will fund a pivotal HOPE study and regulatory preparation. Separately, Atavistik Bio raised $160 million to develop allosteric modulators targeting blood disorders, including myelofibrosis and hereditary hemorrhagic telangiectasia (HHT). Investors cited the company’s mechanistic approach to precision modulation as the rationale for the round. Both financings underscore continued investor appetite for modalities that address neurodegeneration and hematologic diseases, and they reinforce a financing market willing to back platform and mechanistic approaches ahead of late‑stage validation.